A detailed history of Pnc Financial Services Group, Inc. transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 3,210 shares of CPRX stock, worth $73,188. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,210
Previous 2,707 18.58%
Holding current value
$73,188
Previous $41,000 53.66%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$15.19 - $21.35 $7,640 - $10,739
503 Added 18.58%
3,210 $63,000
Q2 2024

Aug 09, 2024

BUY
$14.68 - $16.92 $1,835 - $2,115
125 Added 4.84%
2,707 $41,000
Q1 2024

May 10, 2024

SELL
$13.18 - $17.11 $136,782 - $177,567
-10,378 Reduced 80.08%
2,582 $41,000
Q4 2023

Feb 09, 2024

BUY
$11.78 - $17.29 $20,249 - $29,721
1,719 Added 15.29%
12,960 $217,000
Q3 2023

Nov 13, 2023

BUY
$11.69 - $15.02 $39,208 - $50,377
3,354 Added 42.53%
11,241 $131,000
Q2 2023

Aug 11, 2023

BUY
$11.5 - $18.08 $54,372 - $85,482
4,728 Added 149.67%
7,887 $106,000
Q1 2023

May 15, 2023

BUY
$14.34 - $21.05 $917 - $1,347
64 Added 2.07%
3,159 $52,000
Q4 2022

Feb 10, 2023

BUY
$12.25 - $19.5 $3,858 - $6,142
315 Added 11.33%
3,095 $57,000
Q3 2022

Nov 10, 2022

BUY
$7.06 - $15.52 $16,760 - $36,844
2,374 Added 584.73%
2,780 $35,000
Q4 2021

Feb 11, 2022

BUY
$5.21 - $7.45 $2,115 - $3,024
406 New
406 $2,000
Q4 2019

Feb 07, 2020

SELL
$3.67 - $5.7 $950,977 - $1.48 Million
-259,122 Closed
0 $0
Q3 2019

Nov 08, 2019

BUY
$3.89 - $7.43 $1.01 Million - $1.93 Million
259,122 New
259,122 $1.38 Million
Q3 2018

Nov 09, 2018

SELL
$2.81 - $3.78 $2,810 - $3,780
-1,000 Closed
0 $0
Q2 2018

Aug 10, 2018

BUY
$2.26 - $3.84 $2,260 - $3,840
1,000 New
1,000 $0

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.34B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.